戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nal detachment associated with proliferative vitreoretinopathy.
2 al hemangioblastomas, and familial exudative vitreoretinopathy.
3 ch as diabetic retinopathy and proliferative vitreoretinopathy.
4 ascular retinopathies, such as proliferative vitreoretinopathy.
5 proliferative diseases such as proliferative vitreoretinopathy.
6 cations in the pathogenesis of proliferative vitreoretinopathy.
7 ccess, 6 eyes (5.5%) developed proliferative vitreoretinopathy.
8 n experimental rabbit model of proliferative vitreoretinopathy.
9 ation and pathologies, such as proliferative vitreoretinopathy.
10 ecurrent detachments caused by proliferative vitreoretinopathy.
11 0-54.3%; four studies) in familial exudative vitreoretinopathy.
12 ical options for prevention of proliferative vitreoretinopathy.
13 imilar to the features of familial exudative vitreoretinopathy.
14 alling and are mutated in familial exudative vitreoretinopathy.
15  and a female infant with familial exudative vitreoretinopathy.
16 ated in Norrie disease or familial exudative vitreoretinopathy.
17 otic diseases, in RPE cells in proliferative vitreoretinopathy.
18  could be useful in preventing proliferative vitreoretinopathy.
19  RPE dedifferentiation such as proliferative vitreoretinopathy.
20 ch as diabetic retinopathy and proliferative vitreoretinopathy.
21 proliferative diseases such as proliferative vitreoretinopathy.
22 ogression in a rabbit model of proliferative vitreoretinopathy.
23 related human diseases such as proliferative vitreoretinopathy.
24 lmitis, retinal detachment and proliferative vitreoretinopathy.
25 the current approach to treatment of various vitreoretinopathies.
26 ic interventions in preventing proliferative vitreoretinopathy?
27 tes of cataract (0% vs. 4.6%), proliferative vitreoretinopathy (0.1% vs. 2.0%), and retinal detachmen
28  epiretinal membrane (45.17%), proliferative vitreoretinopathy (0.98%), and endophthalmitis (0.14%).
29 rant RD (-0.27, P < .001), and proliferative vitreoretinopathy (-0.68, P < .001) correlated with anat
30 h vitreous hemorrhage (1), and proliferative vitreoretinopathy (1).
31 ontrol, P = .0001) and primary proliferative vitreoretinopathy ([15.53%] pandemic, [6.9%] control, P
32  surgery is the development of proliferative vitreoretinopathy, accounting for the failure of 7% to 1
33  Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is a rare disorder characteriz
34  Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is a rare genetic (CAPN5) auto
35  autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV, OMIM #193235).
36 istics of patients who develop proliferative vitreoretinopathy after retinoblastoma treatment.
37  implicated in the etiology of proliferative vitreoretinopathy and age-related macular degeneration.
38 s of such retinal disorders as proliferative vitreoretinopathy and age-related macular degeneration.
39 s reparative processes such as proliferative vitreoretinopathy and as a laboratory tool for RPE behav
40 ments associated with anterior proliferative vitreoretinopathy and epiciliary membranes.
41 inal membranes associated with proliferative vitreoretinopathy and idiopathic epiretinal membranes.
42 y more epiretinal membrane and proliferative vitreoretinopathy and lower single-surgery anatomic succ
43 ed redetachment resulting from proliferative vitreoretinopathy and required additional surgery.
44 opathy autosomal dominant familial exudative vitreoretinopathy and suggest that it also may be a susc
45 osis but may be complicated by proliferative vitreoretinopathy and tractional retinal detachment.
46 n on the optic disc along with proliferative vitreoretinopathy and tractional retinal detachment.
47  be a useful strategy to treat proliferative vitreoretinopathy and uveitis, ocular diseases initiated
48  recurrent retinal detachment, proliferative vitreoretinopathy, and a lack of postoperative OCT data
49 ailure to reattach the retina, proliferative vitreoretinopathy, and delayed reabsorption of subretina
50 tinal redetachment by limiting proliferative vitreoretinopathy, and protect against photoreceptor cel
51 ment of retinal detachment and proliferative vitreoretinopathy, and the number of secondary surgeries
52 imetabolites for modulation of proliferative vitreoretinopathy, antimicrobial agents for endophthalmi
53 ome) and CAPN5 NIV (neovascular inflammatory vitreoretinopathy)-as well as variants in genes not prev
54 ted (RD unrelated to trauma or proliferative vitreoretinopathy at presentation).
55                                Proliferative vitreoretinopathy B (retinal wrinkling/vessel tortuosity
56  disease, present with primary proliferative vitreoretinopathy, be lost to follow-up, and have worse
57 nce of a fellow (beta = 14.5), proliferative vitreoretinopathy (beta = 12.8), and greater number of r
58                                Proliferative vitreoretinopathy C (27/100) was clinically divided into
59               CAPN5 Neovascular Inflammatory Vitreoretinopathy (CAPN5-NIV; OMIM 193235) is a poorly-u
60 ry scleral buckle (4.45/4.60), proliferative vitreoretinopathy detachments (4.57/4.45), advanced diab
61                                Proliferative vitreoretinopathy developed in response to subretinal or
62                                Proliferative vitreoretinopathy did not develop in saline-treated cont
63  the eye in patients with familial exudative vitreoretinopathy (FEVR) and retinopathy of prematurity
64 crostructural features of familial exudative vitreoretinopathy (FEVR) have not been well described.
65 d with autosomal dominant familial exudative vitreoretinopathy (FEVR) in families linking to the EVR1
66  pathological features of familial exudative vitreoretinopathy (FEVR) in human patients.
67                           Familial exudative vitreoretinopathy (FEVR) is a genetically heterogeneous
68                           Familial exudative vitreoretinopathy (FEVR) is a hereditary eye disorder th
69                           Familial exudative vitreoretinopathy (FEVR) is a human disease characterize
70                           Familial exudative vitreoretinopathy (FEVR) is a nonsyndromic autosomal dom
71                           Familial exudative vitreoretinopathy (FEVR) is a rare finding in patients w
72                           Familial exudative vitreoretinopathy (FEVR) is an inherited blinding disord
73                           Familial exudative vitreoretinopathy (FEVR) is an inherited blinding disord
74                           Familial exudative vitreoretinopathy (FEVR) is an inherited childhood blind
75                           Familial exudative vitreoretinopathy (FEVR) is characterized by delayed ret
76 thy of prematurity (ROP), familial exudative vitreoretinopathy (FEVR), and telomere biology disorders
77 typically associated with familial exudative vitreoretinopathy (FEVR), can result from mutations in K
78  (KO) ) mouse, a model of familial exudative vitreoretinopathy (FEVR), developmental hypovascularizat
79 pants with a diagnosis of familial exudative vitreoretinopathy (FEVR), Norrie disease, Coats' disease
80 a known family history of familial exudative vitreoretinopathy (FEVR), were also excluded.
81  and a candidate gene for familial exudative vitreoretinopathy (FEVR), which is caused by defects in
82 n both Norrie disease and familial exudative vitreoretinopathy (FEVR).
83 ed in the pathogenesis of familial exudative vitreoretinopathy (FEVR, MIM # 133780).
84 oxocariasis (n = 22; 4%), familial exudative vitreoretinopathy (FEVR; n = 18; 3%), rhegmatogenous ret
85 ent retinal detachments due to proliferative vitreoretinopathy, focusing on the most recent reports i
86 us hemorrhage, dense cataract, proliferative vitreoretinopathy, giant retinal tear, among others) wer
87  years and those with advanced proliferative vitreoretinopathy, giant retinal tear, trauma, or second
88                      Eyes with proliferative vitreoretinopathy, giant retinal tears, previous invasiv
89  surgery, former VR surgery or proliferative vitreoretinopathy grade C or higher were excluded.
90 h vision loss for >= 3 months, proliferative vitreoretinopathy grade C or worse, a demarcation line,
91                                Proliferative vitreoretinopathy grade CP incidence was compared using
92                           Familial exudative vitreoretinopathy has a wide range of unrecognized or un
93 rent retinal detachment due to proliferative vitreoretinopathy has grown concomitantly with more expe
94 r cell involvement, similar to proliferative vitreoretinopathy in humans.
95 ein dampens the development of proliferative vitreoretinopathy in mice.
96 risk of added vision loss posed by exudative vitreoretinopathy in patients with RP, a heightened awar
97 The incidence of postoperative proliferative vitreoretinopathy in the PPV/SB group (11.7%) was lower
98                                Proliferative vitreoretinopathy in turn increases the risk of recurren
99 reoretinopathies, such as familial exudative vitreoretinopathies including Norrie disease.
100 he later contractile stages of proliferative vitreoretinopathy, interleukin-1 beta (IL-1 beta) and tr
101                                Proliferative vitreoretinopathy is a vision-threatening response to pe
102                                Proliferative vitreoretinopathy is caused by the contraction of fibrot
103 inal detachment complicated by proliferative vitreoretinopathy is now most frequently treated by pars
104                                   Coats-like vitreoretinopathy is present in up to 5% of all RP patie
105                    Significant proliferative vitreoretinopathy, lens status, and macular attachment s
106     Complications consisted of proliferative vitreoretinopathy (n = 13), recurrent neovascularization
107 l vasculitis (n = 4, 6%), familial exudative vitreoretinopathy (n = 3, 4%), and others (n = 12, 18%).
108  criteria included significant proliferative vitreoretinopathy or previous retinal detachment repair
109 2 were complicated (history of proliferative vitreoretinopathy or trauma-related RDs at presentation)
110 revious diagnosis of PDR, DME, proliferative vitreoretinopathy, or treatment used in the care of VTDR
111 Screening genomic DNA samples from exudative vitreoretinopathy patients identifies three distinct mut
112 time of presentation of Coats-like exudative vitreoretinopathy, pedigree analysis, genetic testing, r
113                      Eyes with proliferative vitreoretinopathy, previous glaucoma surgery, and giant
114 hegmatogenous RD (RRD) without proliferative vitreoretinopathy (PVR) (n = 30), PVR (n = 16) and proli
115 t developed a third RRD due to proliferative vitreoretinopathy (PVR) (n = 43) were 110% more likely t
116 amponading agent, preoperative proliferative vitreoretinopathy (PVR) and axial length (AL) of the eye
117 inal membranes associated with proliferative vitreoretinopathy (PVR) and idiopathic epiretinal membra
118 raction) that are intrinsic to proliferative vitreoretinopathy (PVR) and induce the disease itself.
119 n vivo models for experimental proliferative vitreoretinopathy (PVR) and provide a detailed protocol
120 L) algorithm design to predict proliferative vitreoretinopathy (PVR) by ophthalmologists without codi
121                                Proliferative vitreoretinopathy (PVR) exemplifies a disease that is di
122      During the progression of proliferative vitreoretinopathy (PVR) following ocular trauma, previou
123 th factor (PDGF) contribute to proliferative vitreoretinopathy (PVR) in experimental models of the di
124  levels and the development of proliferative vitreoretinopathy (PVR) in patients with rhegmatogenous
125 ) is required for experimental proliferative vitreoretinopathy (PVR) in rabbits.
126                                Proliferative vitreoretinopathy (PVR) is a blinding condition caused b
127                                Proliferative vitreoretinopathy (PVR) is a blinding disease associated
128                                Proliferative vitreoretinopathy (PVR) is a complication of retinal det
129                                Proliferative vitreoretinopathy (PVR) is a complication of retinal det
130                                Proliferative vitreoretinopathy (PVR) is a complication that develops
131                                Proliferative vitreoretinopathy (PVR) is a disorder characterized by t
132                                Proliferative vitreoretinopathy (PVR) is a major cause for failure of
133                                Proliferative vitreoretinopathy (PVR) is a nonneovascular blinding dis
134                                Proliferative vitreoretinopathy (PVR) is a recurring and problematic d
135                                Proliferative vitreoretinopathy (PVR) is a serious complication of ret
136                                Proliferative vitreoretinopathy (PVR) is a serious problem in vitreore
137                                Proliferative vitreoretinopathy (PVR) is characterized by the prolifer
138                        Primary proliferative vitreoretinopathy (PVR) is established as an important c
139                                Proliferative vitreoretinopathy (PVR) is mediated by proliferation and
140                                Proliferative vitreoretinopathy (PVR) is the leading cause of recurren
141                                Proliferative vitreoretinopathy (PVR) is the leading cause of retinal
142                                Proliferative vitreoretinopathy (PVR) is the major cause for surgical
143                                Proliferative vitreoretinopathy (PVR) is the primary cause of failure
144 F-alpha is widely expressed in proliferative vitreoretinopathy (PVR) membranes and is present in the
145                                Proliferative vitreoretinopathy (PVR) occurs in approximately 10% of p
146 itreous cytokine expression of proliferative vitreoretinopathy (PVR) patients.
147 ts with retinal detachment and proliferative vitreoretinopathy (PVR) plus vitreous from eyes obtained
148                                Proliferative vitreoretinopathy (PVR) remains the most common cause of
149 ctive review of three cases of proliferative vitreoretinopathy (PVR) that developed after successful
150                                Proliferative vitreoretinopathy (PVR) thwarts the repair of rhegmatoge
151 ailure rates when grade 0 or B proliferative vitreoretinopathy (PVR) was present and higher level 2 f
152 ached in 45% eyes, and grade C proliferative vitreoretinopathy (PVR) was present in 12%.
153 vent or inhibit development of proliferative vitreoretinopathy (PVR) was tested in a dispase-induced
154 ith primary RRD complicated by proliferative vitreoretinopathy (PVR) with subretinal bands interferin
155 ) isoforms are associated with proliferative vitreoretinopathy (PVR), a sight-threatening complicatio
156 PE-19 is an in vitro model for proliferative vitreoretinopathy (PVR), an aberrant wound healing respo
157 e of NF-kappaB in experimental proliferative vitreoretinopathy (PVR), and may offer a novel approach
158 ormed in patients with primary proliferative vitreoretinopathy (PVR), and/or the necessity of a prima
159 ften with macular involvement, proliferative vitreoretinopathy (PVR), chronic duration, and poor visu
160 ex, foveal detachment, grade C proliferative vitreoretinopathy (PVR), inferior retinal breaks, inferi
161  visual acuity (BCVA), primary proliferative vitreoretinopathy (PVR), proportion lost to follow-up, a
162                             In proliferative vitreoretinopathy (PVR), retinal pigment epithelial (RPE
163 t that drives RPE responses in proliferative vitreoretinopathy (PVR), suggesting that the IGF system
164 ith (n = 7) or without (n = 9) proliferative vitreoretinopathy (PVR), vitreous hemorrhage (n = 10), v
165 cular hole (n = 33), recurrent proliferative vitreoretinopathy (PVR)-related retinal detachment (n =
166 macular degeneration (AMD) and proliferative vitreoretinopathy (PVR).
167 macular degeneration (AMD) and proliferative vitreoretinopathy (PVR).
168 onset, and presence of primary proliferative vitreoretinopathy (PVR).
169 c diseases of the eye, such as proliferative vitreoretinopathy (PVR).
170  epiretinal membranes found in proliferative vitreoretinopathy (PVR).
171 ution to the events leading to proliferative vitreoretinopathy (PVR).
172 ered the most common cause for proliferative vitreoretinopathy (PVR).
173 its against the development of proliferative vitreoretinopathy (PVR).
174 es) due to variable degrees of proliferative vitreoretinopathy (PVR).
175 iabetic retinopathy (PDR), and proliferative vitreoretinopathy (PVR).
176 etinal surgery for established proliferative vitreoretinopathy (PVR).
177 breaks, mostly with associated proliferative vitreoretinopathy (PVR).
178  retinal detachment related to proliferative vitreoretinopathy (PVR).
179 t in the context of high-grade proliferative vitreoretinopathy (PVR).
180 of a blinding condition called proliferative vitreoretinopathy (PVR).
181 e kinase inhibitor, to prevent proliferative vitreoretinopathy (PVR).
182 macular degeneration (AMD) and proliferative vitreoretinopathy (PVR).
183 oblasts to induce experimental proliferative vitreoretinopathy (PVR).
184  context of in vitro models of proliferative vitreoretinopathy (PVR).
185  to establish its relevance to proliferative vitreoretinopathy (PVR).
186 nvestigation were: (1) grade B proliferative vitreoretinopathy (PVR; n = 917), (2) grade C-1 PVR (n =
187  0.32 [0.11-0.94]; P = 0.039), proliferative vitreoretinopathy (PVR; OR, 0.39 [0.16 - 0.92]; P = 0.03
188  CNV recurrence (OR, 2.6), and proliferative vitreoretinopathy (PVR; OR, 17.6) were statistically sig
189 : 87%; aZ3: 71%; P < 0.01) and proliferative vitreoretinopathy (pZ3 66%; aZ3 47%; P < 0.03).
190 omes and a lower postoperative proliferative vitreoretinopathy rate.
191         Here, we show that, in proliferative vitreoretinopathy, recruitment of macrophages and direct
192 intraocular fibrosis, known as proliferative vitreoretinopathy, results in a blinding tractional reti
193  retinal detachment (3.65) and proliferative vitreoretinopathy stages A, B, and C (2.06) were elevate
194 al study of patients entered into the French Vitreoretinopathy Study Group database.
195 typical of human hypovascularization-related vitreoretinopathies, such as familial exudative vitreore
196  age at presentation of Coats-like exudative vitreoretinopathy was 18 years (range, 1-41 years).
197                                Proliferative vitreoretinopathy was a significant prognostic factor fo
198                                Proliferative vitreoretinopathy was the most common cause for redetach
199 an ophthalmic biobank (421 participants with vitreoretinopathies were included in this study).
200 ice for management of a variety of pediatric vitreoretinopathies were offered participation in an oph
201                        Patients with various vitreoretinopathies were prospectively enrolled in an op
202 th RP and demonstrating Coats-like exudative vitreoretinopathy were included.

 
Page Top